All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Efficacy of Edaravone in Combination with Dihydropyridine Calcium Ion Antagonist on Hypertensive Intracerebral Hemorrhage

Author(s): YANG LI, XIU-QIN WU, QI FAN, JIA-ZE LI, FU-SHUN WANG, JIAN-ZHONG LI, JIA YE*
Psychological center, school of management, Nanjing forest police college, Nanjing, Jiangsu 210023, 1School of Psychology, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, 2Nanjing University of Chinese Medicine Hanlin College, Nanjing, Jiangsu 225300,3School of Psychology, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, 4School of foreign languages, Nanjing Agricultural University, Nanjing, Jiangsu, 210026, P.R.China, 5Department of nursing, Jiading District mental health center of Shanghai, No. 701, Wang An Road, Jiading District, Shanghai 201800, China

Correspondence Address:
JIA YE, School of foreign languages, Nanjing Agricultural University, Nanjing, Jiangsu, 210026, P.R.China, E-mail: [email protected]


This research article planned to investigate the efficacy of edaravone in combination with dihydropyridine calcium ion antagonist on hypertensive intracerebral hemorrhage. Between February 2017 and January 2019, we collected the clinical data from 126 hypertensive intracerebral hemorrhage patients and divided them into the control group and observation group, with 63 patients in each group. Patients in two groups all underwent the regular treatment, while those in the observation group took edaravone in combination with dihydropyridine calcium ion antagonist (nimodipine) for treatment. Following the treatment, we compared the clinical efficacy, plasmin endothelin 1, volume of edema and hematoma and National Institute of Health stroke scale scores. In the control group, the total effectiveness rate of treatment was 71.44 %, significantly lower than that of the observation group (p<0.05); following treatment, the level of endothelin 1 in plasma and the volumes of edema and hematoma were all decreased as compared to those before treatment and the decrease in the observation group was more evident (p<0.01). Before treatment, difference in the National Institute of Health stroke scale scores between the control group and the observation group was not evident (p>0.05), while after 2 and 4 w of treatment, patients in the observation group had scores of (12.43±4.07) and (7.52±1.84) points, significantly higher than those in the control group (p<0.01). Combined medication of edaravone and dihydropyridine calcium ion antagonist can benefit the patients with promising efficacy and improvement in nervous function.

Full-Text | PDF